Outsourcing-Pharma.com’s Melissa Fassbender recently posted an article on a talk she had with James M. Anderson, M.D., Ph.D., Deputy Director, NIH Division of Program Coordination, Planning and Strategic Initiatives. This exchange reveals information on clinical grade stem line development that is hoped to help accelerate early-stage clinical research for diseases including Alzheimer’s, Parkinson’s, spinal cord injury, diabetes and muscular dystrophy. Anderson talks about how clinical grade cells are developed under regulations and quality control measures that ensure quality and safety standards of the cells for potential clinical applications in humans. Click here to read Fassbender’s article and contact us if you need help with your cell therapy regulatory filings or clinical trials. Pearl has extensive experience with cell therapy products.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.